Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Inclusion Criteria: * Subjects must provide informed consent * Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on the face or scalp * Subject at least 18 years of age * Female subjects must be of either: * Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or, * Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to study treatment, to rule out pregnancy * Female subjects of childbearing potential must be willing to consent to using highly effective methods of contraception Exclusion Criteria: * Location of the selected treatment area: * on any location other than the face or scalp * on the periorbital skin * within 5 cm of an incompletely healed wound * within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) * Prior treatment with ingenol mebutate gel on face or scalp (previous treatment on trunk and extremities acceptable) * Selected treatment area lesions that have atypical clinical appearance * History or evidence of skin conditions other than the trial indication that would interfere with evaluation of the trial medication in the selected treatment area * Anticipated need for hospitalization or out-patient surgery prior to Day 15 in the first treatment cycle * Known sensitivity or allergy to any of the ingredients in ingenol mebutate gel * P…